Key facts
- This page summarizes Thomas Richard Kassberg's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2025, 20:19.
Thomas Richard Kassberg - 01 Mar 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)
- Reporting relationship
- CBO & EVP
- Issuer ticker
- RARE
- Reported as of
- 01 Mar 2025
- Net transaction value
- -$275,582
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 20:19:57 UTC
- Prior SEC filing
- 02 Oct 2024
- Next SEC filing
- 30 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karah Parschauer, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Richard Kassberg filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 02 Oct 2024.
- Current net transaction value: -$275,582.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RARE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +18,443
- Change %
- +7.3%
- Price
- $0.000000
- Shares after
- 271,266
- Date
- 01 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
RARE
transaction
Common Stock
Sale
- Transaction value
- $253,779
- Shares
- -6,028
- Change %
- -2.2%
- Price
- $42.10
- Shares after
- 265,238
- Date
- 03 Mar 2025
- Ownership
- Direct
- Footnotes
- F2, F3
RARE
transaction
Common Stock
Tax liability
- Transaction value
- $21,803
- Shares
- -508
- Change %
- -0.19%
- Price
- $42.92
- Shares after
- 264,730
- Date
- 03 Mar 2025
- Ownership
- Direct
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
Footnote F2
Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F4
Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
Footnote F5
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.